PITTSBURGH (AP) – Mylan Inc. said on Dec. 27 that the Food and Drug Administration approved the drugmaker’s generic version of the high blood pressure treatment Teveten.
Teveten, or eprosartan, is marketed by Abbott Laboratories Inc. Mylan is shipping generic Teveten in strengths of 400 milligrams and 600 milligrams and will have six months of marketing exclusivity.
The Associated Press
